Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
24.04.25
09:25 Uhr
11,500 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,30011,70024.04.
11,40011,70024.04.

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03:29Akeso Receives FDA Approval For Penpulimab-kcqx To Treat Advanced Nasopharyngeal Carcinoma1
01:49AKESO (09926): VOLUNTARY ANNOUNCEMENT - FDA APPROVED ANNIKO (PENPULIMAB-KCQX, PD-1) IN TWO INDICATIONS FOR COMPREHENSIVE TREATMENT OF ADVANCED NASOPHARYNGEAL ...-
AKESO Aktie jetzt für 0€ handeln
DoFDA genehmigt neues Medikament von Akeso Biopharma zur Behandlung von Nasopharynxkarzinom1
DoFDA approves Akeso Biopharma's new drug for nasopharyngeal carcinoma treatment2
DoHSI Closes at 21,909, Down 162 pts; HSTI Closes at 4,975, Down 73 pts; MEITUAN Down over 5%; ASCENTAGE, AKESO, CHICMAX, CQRC BANK, NISSIN FOODS Hit New Highs; Market Turnover Rises5
MiWith new trial win, Akeso bispecific shows prior success against Keytruda is no 'fluke'2
MiHSI Up 510 pts; HSTI Up 150 pts; BABA Up over 5%; HK & CHINA GAS, CHINA EAST EDU, AKESO, POP MART, BCQ Hit New Highs; Market Turnover Rises7
MiHSI Up 519 pts; HSTI Up 152 pts; BABA Up over 5%; TENCENT Up over 3%; AIA Up over 3%; HK & CHINA GAS, AKESO, CHINA EAST EDU, SHENZHEN INT'L Hit New Highs10
MiAkeso's Ivonescimab Shows Promising Results In Phase III Trial For Advanced Lung Cancer Treatment2
MiAkeso, Inc.: Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in ...42HONG KONG, April 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is both pleased and honored to announce that its global first-in-class...
► Artikel lesen
MiAKESO (09926): VOLUNTARY ANNOUNCEMENT - AK112-306/HARMONI-6 MET PRIMARY ENDPOINT OF PFS SUPERIORITY IVONESCIMAB PLUS CHEMO DEMONSTRATED A STATISTICALLY ...1
MoAKESO (09926): VOLUNTARY ANNOUNCEMENT - NMPA APPROVED NDA OF (EBDAROKIMAB, IL-12/IL-23)1
02.04.CCBI Lifts AKESO's TP to $90, Rating Kept Outperform9
02.04.HTSC Raises 2025/2026 NP Forecasts for AKESO , Lifts TP to $103.681
01.04.HSI Closes at 23,206, Up 87 pts; HSTI Closes at 5,407, Up 12 pts; CSPC PHARMA Up over 10%; LAOPU GOLD, CENTRAL NEW EGY, AKESO, ANE, LONKING Hit New Highs; Market Turnover Rises11
01.04.HSI Up 244 pts; HSTI Up 97 pts; CSPC PHARMA Up over 12%; HANSOH PHARMA, CENTRAL NEW EGY, AKESO, LAOPU GOLD, 3SBIO Hit New Highs7
01.04.AKESO Leaps 12%+; 2 Blockbuster Bi-specific Antibodies Expected to Cover 2K Hospitals This Yr4
01.04.BOCI Lifts AKESO's TP to $87, Rating Reiterated at Buy3
30.03.Akeso, Inc.: Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies103Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline...
► Artikel lesen
21.03.Akeso, Inc.: Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting119HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at...
► Artikel lesen
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3